Antibacterials (ABX) Practice Exam

Intra‑abdominal infections require reliable anaerobic coverage because gut flora include anaerobes that drive many of these infections. Beta-lactamase inhibitors extend the activity of a beta-lactam by protecting it from enzymes produced by these bacteria, enabling the antibiotic to cover anaerobes more effectively. Piperacillin-tazobactam combines a broad-spectrum penicillin with an inhibitor, giving robust activity against anaerobes and a wide range of Gram-positive, Gram-negative, and some resistant organisms, including Pseudomonas. This makes it a common and practical choice for empiric therapy in mixed intra‑abdominal infections. Other options either have less reliable anaerobic coverage, are less suitable for severe intra‑abdominal disease, or are reserved for different clinical scenarios (for example, highly broad agents reserved for resistant cases, or oral regimens with limited efficacy in this setting).